IL283409B1 - History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing them - Google Patents

History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing them

Info

Publication number
IL283409B1
IL283409B1 IL283409A IL28340921A IL283409B1 IL 283409 B1 IL283409 B1 IL 283409B1 IL 283409 A IL283409 A IL 283409A IL 28340921 A IL28340921 A IL 28340921A IL 283409 B1 IL283409 B1 IL 283409B1
Authority
IL
Israel
Prior art keywords
heteroaryl
pyrrolo
carbonyl
pyridine
phenyl
Prior art date
Application number
IL283409A
Other languages
English (en)
Hebrew (he)
Other versions
IL283409A (en
Original Assignee
Nimbus Lakshmi Inc
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nimbus Lakshmi Inc, Takeda Pharmaceuticals Co filed Critical Nimbus Lakshmi Inc
Publication of IL283409A publication Critical patent/IL283409A/en
Publication of IL283409B1 publication Critical patent/IL283409B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL283409A 2018-11-30 2021-05-24 History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing them IL283409B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773620P 2018-11-30 2018-11-30
PCT/US2019/063510 WO2020112937A1 (en) 2018-11-30 2019-11-27 Tyk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
IL283409A IL283409A (en) 2021-07-29
IL283409B1 true IL283409B1 (en) 2026-03-01

Family

ID=70848642

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283409A IL283409B1 (en) 2018-11-30 2021-05-24 History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing them

Country Status (8)

Country Link
US (2) US11053241B2 (https=)
EP (1) EP3886843A4 (https=)
JP (3) JP7530360B2 (https=)
CN (1) CN113271938A (https=)
AU (1) AU2019389025B2 (https=)
CA (1) CA3120866A1 (https=)
IL (1) IL283409B1 (https=)
WO (1) WO2020112937A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
JP7530360B2 (ja) 2018-11-30 2024-08-07 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用
EP4269404A4 (en) * 2020-12-25 2024-12-04 Xizang Haisco Pharmaceutical Co., Ltd. KETOHEXOKINASE INHIBITORS AND USE THEREOF
EP4308556A4 (en) 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
TW202425965A (zh) * 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
CN115974751A (zh) * 2022-12-13 2023-04-18 山东能源集团新材料有限公司 一种吡拉西坦制备方法及系统
AU2023410062A1 (en) * 2022-12-22 2025-08-07 Protekt Therapeutics Ltd. Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors
WO2025010294A2 (en) * 2023-07-03 2025-01-09 Blossomhill Therapeutics, Inc. Macrocyclic compounds and use as tyk2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11878978B1 (en) 2023-09-06 2024-01-23 King Faisal University Pyrrolo[2,3-c]quinoline compounds as CK2 inhibitors
CN117342955A (zh) * 2023-10-08 2024-01-05 盐城师范学院 一种制备4’-甲基-联苯-2-胺的方法
WO2025222103A1 (en) * 2024-04-19 2025-10-23 Raythera, Inc. Stat6 modulators and methods of uses thereof
WO2025264818A1 (en) * 2024-06-20 2025-12-26 Raythera, Inc. Stat6 modulators and methods of uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
ID24300A (id) 1997-08-05 2000-07-13 Pfizer Prod Inc 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
CA2569887A1 (en) * 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
ATE527258T1 (de) 2004-07-28 2011-10-15 Takeda Pharmaceutical Pyrroloä2,3-cüpyridinverbindung, verfahren zu deren herstellung und anwendung
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
EP3080131B1 (en) 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
JP6484253B2 (ja) 2014-05-01 2019-03-13 ノバルティス アーゲー Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物
JP7125385B2 (ja) 2016-08-08 2022-08-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｌｒ７／８アンタゴニストおよびそれらの使用
EP3848370B1 (en) * 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
US11370794B2 (en) * 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
JP7530360B2 (ja) 2018-11-30 2024-08-07 武田薬品工業株式会社 Ｔｙｋ２阻害剤およびその使用

Also Published As

Publication number Publication date
JP7530360B2 (ja) 2024-08-07
EP3886843A4 (en) 2022-08-31
IL283409A (en) 2021-07-29
AU2019389025B2 (en) 2025-07-24
US11834449B2 (en) 2023-12-05
CN113271938A (zh) 2021-08-17
CA3120866A1 (en) 2020-06-04
JP2026053668A (ja) 2026-03-25
AU2019389025A1 (en) 2021-06-17
US11053241B2 (en) 2021-07-06
EP3886843A1 (en) 2021-10-06
US20220106306A1 (en) 2022-04-07
JP2022509260A (ja) 2022-01-20
WO2020112937A1 (en) 2020-06-04
US20200172540A1 (en) 2020-06-04
JP2024160253A (ja) 2024-11-13

Similar Documents

Publication Publication Date Title
IL283409B1 (en) History of phenyl/heteroaryl-7-[(heteroaryl-2-carbonyl)-amino]-h1-pyrrolo[3,2-c]pyridine-4-carboxylic acid methylamide and pharmaceutical composition containing them
EP4072593A4 (en) BIOACTIVABLE CYTOKINE DRUGS AND ASSOCIATED METHODS OF USES
AU2022221446A1 (en) Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
PH12015502792A1 (en) Crystalline bromodomain inhibitors
IL281924A (en) New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
IL285008A (en) Methods for the production and use of myceliated amino acid-supplemented food compositions
ZA202202932B (en) Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
EP3250572A4 (en) Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
SG11202111701XA (en) Coated drug compositions and methods of preparing the same
IL252578B (en) History of 1h- pyrazolo (3.4-c) [5.1] naphthyridine 4-(5h)-one and pharmaceutical preparations containing them
SG11202105730TA (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
EP3312175A4 (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
SG11201400092VA (en) Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
SG11202107848TA (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
IL311733A (en) Hydrochloride salt of inupdanant, pharmaceutical preparations and methods of using it
IL280376A (en) The history of boronic acid, its preparation and pharmaceutical preparations containing it
SG11202007726RA (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same
EP3898582A4 (en) NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY APPROVED SALT THEREOF, COMPOSITION THEREOF, AND METHODS OF USE THEREOF
EP3248981A4 (en) C14-hydroxyl esterified amino acid derivatives of triptolide, and preparation method and use thereof
EP3813842A4 (en) PHARMACEUTICAL COMPOSITION AND MANUFACTURING PROCESS THEREOF
IL286416A (en) Pharmaceutical formulations of abiraterone-ring oligomer and methods for their preparation and administration
EP3915986A4 (en) HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THEM AS ACTIVE PRINCIPLE
EP3747896A4 (en) PHARMACEUTICAL COMPOSITION OF ACYLATED DERIVATIVE OF HUMAN INSULIN ANALOGUE AND MANUFACTURING PROCESS FOR IT
ZA202201888B (en) Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient